Skip to main content

Market Overview

The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

Share:
The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on Aug. 13)

  • Iradimed Corp (NASDAQ: IRMD)
  • SurModics, Inc. (NASDAQ: SRDX)

Down In The Dumps

(Stocks hitting 52-week lows on Aug. 13)

  • Acasti Pharma (NASDAQ: ACST)
  • Achaogen Inc (NASDAQ: AKAO)
  • Agile Therapeutics Inc (NASDAQ: AGRX)
  • Arsanis Inc (NASDAQ: ASNS)(reported a wider-than-expected loss for its Q2)
  • aTyr Pharma Inc (NASDAQ: LIFE)
  • Aytu BioScience (NASDAQ: AYTU) (1-for-20 reverse stock split became effective)
  • Cleveland BioLabs, Inc. (NASDAQ: CBLI)
  • DelMar Pharmaceuticals Inc (NASDAQ: DMPI)
  • IntelliPharmaCeutics Intl Inc (USA) (NASDAQ: IPCI)
  • Osiris Therapeutics, Inc. (NASDAQ: OSIR)
  • Portola Pharmaceuticals (NASDAQ: PTLA)
  • Puma Biotechnology Inc (NASDAQ: PBYI)
  • Surface Oncology Inc (NASDAQ: SURF)
  • Synlogic Inc (NASDAQ: SYBX)
  • Titan Medical Inc. (NASDAQ: TMDI)(reacted to the announcement of Q2 results)
  • VBI Vaccines Inc (NASDAQ: VBIV)

Stocks In Focus

Stocks Reacting To Earnings

VolitionRX Ltd (NYSE: VNRX) reported a loss of 15 cents per share for the second quarter, wider than the loss of 13 cents per share last year. Analysts, on average, estimated a loss of 14 cents per share. Cash and cash equivalents as of June 30, 2018 totaled $11.9 million.

The stock rose 3.66 percent to $1.98 in after-hours session.

Cesca Therapeutics Inc (NASDAQ: KOOL) reported second-quarter net revenues of $2 million compared to $3.5 million last year, with the decline attributed to lower AXP sales due to a change in a distributor in China, lower BioArchive device sales and the termination of a royalty payment agreement last year.

The loss per share widened from 12 cents in Q217 to $1.73 in Q218. The stock jumped 11.76 percent to $11.76 percent in after-hours trading.

See Also: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

ENDRA Life Sciences Inc (NASDAQ: NDRA) reported a loss of 47 cents per share for its second quarter compared to a loss of 59 cents per share in the year-ago quarter.

The stock gained 4.01 percent to $2.36 in after-hours trading.

Acer Therapeutics Inc (NASDAQ: ACER) said its second-quarter loss narrowed from $1.29 in Q217 to 64 cents per share in Q218. The consensus estimate had called for a loss of 55 cents per share.

The stock jumped 9.03 percent to $31.62 in after-hours trading.

On The Radar

Earnings

  • Athenex Inc (NASDAQ: ATNX) Q2 EPS $(0.58) Misses $(0.48) Estimate, Sales $11.6M Miss $14.42M Estimate
  • Array Biopharma Inc ( (NASDAQ: ARRY) Q4 EPS $(0.25) Misses $(0.24) Estimate, Sales $35.4M Miss $38.73M Estimate
  • Bioanalytical Systems, Inc. (NASDAQ: BASI)(before the market open)
  • Cancer Genetics Inc (NASDAQ: CGIX) Q2 EPS $(0.13) Beats $(0.16) Estimate, Sales $7.036M Miss $8.3M Estimate
  • Eyenovia Inc (NASDAQ: EYEN) Q2 EPS $(0.33) Beats $(0.42) Est.
  • Urogen Pharma Ltd (NASDAQ: URGN) Q2 EPS $(1.14) Misses $(0.89) Estimate, Sales $364K
  • Neuronetics Inc (NASDAQ: STIM) Q2 EPS $(30.60) Misses $(0.84) Estimate, Sales $13.252M Beat $12.32M Estimate
  • Onconova Therapeutics Inc (NASDAQ: ONTX) Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $485K Beat $220K Estimate
  • OptiNose Inc (NASDAQ: OPTN) Q2 EPS $(0.64) Beats $(0.77) Estimate, Sales $1.274M Beat $1.25M Estimate
  • Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) Q2 EPS $(0.22) Beats $(0.23) Est., Sales $1.33M May Not Compare To $670K Est.
  • aTyr Pharma Inc (NASDAQ: LIFE) (after the market close)
  • Cytori Therapeutics Inc (NASDAQ: CYTX) (after the market close)
  • Biocept Inc (NASDAQ: BIOC) (after the market close)
  • Reshape Lifesciences Inc (NASDAQ: RSLS) (after the market close)
  • RXi Pharmaceuticals Corp (NASDAQ: RXII) (after the market close)
  • Precision Therapeutics Inc (NASDAQ: AIPT) (after the market close)

IPO

Aridis Pharmaceuticals priced its offering of 2 million shares at $13 per share, at the low end of the estimated price range of $13-$15. The shares will begin trading on the Nasdaq under the ticker symbol ARDS.

 

Related Articles (KOOL + ACER)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Top Stories Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com